Sustained enrichment of liver phospholipids and triglycerides in eicosapentaenoate after a bolus intravenous injection of a medium-chain triglycerides:fish oil emulsion to streptozotocin (Type 1) and Goto-Kakizaki (Type 2) diabetic rats.
This study deals with the sustained enrichment of liver phospholipids and triglycerides in long-chain polyunsaturated omega3 fatty acids (omega3) found after the bolus intravenous injection of a novel medium-chain triglyceride:fish oil emulsion (MCT:FO) to streptozotocin (Type 1) and Goto-Kakizaki (Type 2) diabetic rats. Twenty hours after injection of the MCT:FO emulsion, the relative concentration of omega3 was indeed higher in liver phospholipids and triglycerides than that found in rats injected with either saline or a control medium-chain triglyceride:long-chain triglyceride emulsion. This coincided with a decrease in the ponderal percentage of C18:3omega3, C20:4omega6 and/or C22:4omega6 in liver triglycerides. The present study further documents differences between streptozotocin-induced and Goto-Kakizaki diabetic rats in terms of body weight, glycemia, liver triglyceride content and the fatty acid pattern of both liver phospholipids and triglycerides, as well as a close correlation in the latter animals between liver and plasma phospholipids or triglycerides as far as the ratio in the relative concentration of selected fatty acids representative of desaturase and elongase activities is concerned. In light of these and previous findings, it is proposed that the beneficial metabolic and functional events of the MCT:FO emulsion may display not solely a rapid but also sustained time course.
Carpentier
Yvon A
YA
Laboratories of Experimental Surgery and Physiology and Pharmacology, Brussels Free University, B-1070 Brussels, Belgium.
Fontaine
David
D
Otto
Anne
A
Portois
Laurence
L
Fontaine
Jeanine
J
Malaisse
Willy J
WJ
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000378:metabolism / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000139:chemically induced / Q000378:metabolism* / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism* / Q000628:therapy; D015118:Eicosapentaenoic Acid / Q000032:analysis*; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D015525:Fatty Acids, Omega-3 / Q000032:analysis; D043371:Fatty Acids, Omega-6 / Q000032:analysis; D005395:Fish Oils / Q000737:chemistry; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010743:Phospholipids / Q000097:blood / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood / Q000737:chemistry
D005217:Fat Emulsions, Intravenous; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005395:Fish Oils; D010743:Phospholipids; D014280:Triglycerides; D015118:Eicosapentaenoic Acid